CJC-1295 Research: What Published Studies Have Investigated

What is CJC-1295?

What is CJC-1295? It is a synthetic analog of growth-hormone-releasing hormone (GHRH), built on the first 29 residues of human GHRH — the GRF(1-29) fragment also known as sermorelin — carrying four amino-acid substitutions that studies describe as conferring resistance to enzymatic (DPP-IV) degradation. Two forms are described in the literature and in research catalogues. CJC-1295 with DAC carries a Drug Affinity Complex, an albumin-binding element; CJC-1295 without DAC — commonly called mod-GRF 1-29, or CJC-1295 no-DAC — lacks that element. As a GHRH analog this is a neutral molecular definition; the sections below describe what researchers examined, not effects in people.

Molecule properties

CJC-1295 is a peptide analog of GHRH(1-29). In the DAC form, a maleimido-lysine moiety is described as forming a covalent bond with a free thiol on circulating serum albumin; the literature associates that albumin bioconjugation with a substantially extended plasma half-life relative to native GHRH, which is cleared rapidly. The no-DAC form (mod-GRF 1-29) lacks this albumin-binding element, so the two share the same GHRH(1-29) backbone and stabilizing substitutions but differ in whether they carry the DAC moiety. In research catalogues CJC-1295 is supplied as a lyophilized powder, and it is worth keeping the distinction between endogenous GHRH and this synthetic research-grade analog clear. These are molecule facts only — no handling, reconstitution, or dosing guidance is given here.

Mechanisms researchers have examined

The CJC-1295 mechanism literature is anchored in GHRH receptor pharmacology and in the albumin-binding chemistry that defines the DAC form. Each direction below is framed as what researchers examined:

• GHRH-receptor agonism — CJC-1295 is described as binding the growth-hormone-releasing-hormone receptor (GHRH-R) on anterior-pituitary somatotrophs. The canonical downstream cascade characterized in GHRH biology is Gsα → adenylyl cyclase → cAMP → protein kinase A. This is receptor pharmacology, described at the level of the molecule, not an effect on the reader.
• Drug Affinity Complex (albumin binding) — the DAC element is described as bioconjugating to endogenous albumin, and this is the mechanism the literature invokes to explain the prolonged circulating half-life of the DAC form. It is a pharmacokinetic mechanism rather than a pharmacodynamic effect.
• DAC vs no-DAC (mod-GRF 1-29) — drawn plainly as molecule chemistry: the DAC form is associated in the literature with days-long circulation, while the no-DAC form (mod-GRF 1-29) is described as short-acting because it lacks the albumin-binding element. This is a neutral structural distinction, not a comparison of results.
• GH / IGF-1 axis as a measured endpoint — Teichman et al. (2006) and Ionescu & Frohman (2006) measured plasma GH and IGF-1 as pharmacodynamic markers, and Ionescu & Frohman reported that pulsatile GH secretion persisted during continuous stimulation. Described strictly as what the studies measured or observed, never as a benefit to the reader.

The section closes as the literature frames it: CJC-1295 is a GHRH-receptor agonist characterized primarily by its albumin-binding (DAC) pharmacokinetics, and the endpoints in the human studies were secretory and serum markers. This mechanism is kept distinct from that of ipamorelin, a ghrelin / growth-hormone-secretagogue-receptor agonist described on its own page — a different receptor entirely. The two are named only as a mechanistic contrast; this page does not describe combining them.

Research models in the literature

Notably for a research peptide, the CJC-1295 record includes published human pharmacokinetic and pharmacodynamic trials. Teichman et al. (2006, J Clin Endocrinol Metab, PMID 16352683) ran randomized, placebo-controlled ascending-dose trials in healthy adults, measuring plasma GH and IGF-1 over multi-day windows and estimating a multi-day half-life for the DAC form. Ionescu & Frohman (2006, J Clin Endocrinol Metab, PMID 17018654) used overnight sampling to examine whether GH pulsatility is preserved during sustained GHRH stimulation, and reported that it was. Sackmann-Sala et al. (2009, Growth Horm IGF Res, PMID 19386527) carried out a serum proteomic study (2-D gel / mass spectrometry) in healthy men, examining candidate protein-profile markers associated with GH/IGF-1 activity.

On the preclinical side, Alba et al. (2006, Am J Physiol Endocrinol Metab, PMID 16822960) used the GHRH-knockout mouse model to examine whether once-daily CJC-1295 normalizes growth parameters in that model. Read neutrally, the human data here are pharmacokinetic, pharmacodynamic and marker-based — what the trials measured — rather than general therapeutic-outcome claims, and much of the mechanistic detail derives from GHRH biology and from rodent models. The GH and IGF-1 values reported in the human trials are research observations about what those studies measured; they do not describe an effect a reader would experience, and animal or marker findings cannot establish human outcomes.

CJC-1295 among the GH-secretagogue research peptides

In one line: CJC-1295 sits with the GHRH analogs among the growth-hormone-axis research peptides. What distinguishes it as a research target is its albumin-binding (DAC) pharmacokinetics layered onto the GHRH(1-29) backbone shared with fragments such as sermorelin. Related GHRH-analog work is discussed under tesamorelin research, while the downstream IGF-1 LR3 page covers a distinct point in the GH/IGF-1 axis. The ghrelin-mimetic ipamorelin acts on a different receptor and is treated as a separate mechanistic question, not a companion — the contrast is receptor family, not a stack. This is research-focus context rather than any use or combination advice; the detail belongs on each sibling page.

Research-grade sourcing and verification

For laboratory research use only, CJC-1295 is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation, with lot-level verification. Check the exact batch on the self-serve verify tool, and see how to read a COA for what the certificate reports. As a catalogue and identity fact only, Cellworks lists CJC-1295 as a co-formulated CJC-1295 / ipamorelin research blend — the product links below identify those items, with no protocol or combination guidance implied.

Frequently asked questions

Literature cited

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683 (DOI 10.1210/jc.2005-1536).
2. Ionescu M, Frohman LA. “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.” J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID 17018654 (DOI 10.1210/jc.2006-1702).
3. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. “Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.” Growth Horm IGF Res. 2009;19(6):471-477. PMID 19386527 (DOI 10.1016/j.ghir.2009.03.001).
4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.” Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. PMID 16822960 (DOI 10.1152/ajpendo.00201.2006).